Researchers have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen.
Results of a new study, which was presented Saturday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago, point to a previously unrecognized role of the androgen receptor.
Study Confirms 3D Imaging Detects More Breast Cancer Than Digital Mammography Alone
The largest study of its kind to date has revealed that three-dimensional imaging finds more breast cancers than traditional, digital mammography alone.
Advertisement
Although this receptor (protein) is expressed in nearly all prostate cancers, it also is expressed in most breast cancers. Now scientists have found that estrogen receptor alpha—a main driver of estrogen-fueled breast cancer—may rely on the androgen receptor for its function.
In a study funded by the U.S. Department of Defense Breast Cancer Research Program, Jennifer Richer, PhD, from the University of Colorado Anschutz Medical Campus in Aurora, and her colleagues studied 192 women with estrogen receptor-positive breast cancers. They found that women were 4.4 times more likely to have a cancer recurrence during tamoxifen treatment when their main tumor had a high ratio (2:1 or greater) of androgen receptor-positive cells to estrogen receptor-positive cells.
![New Virus Kills Triple Negative Breast Cancer Cells and Tumor Cells]( "New Virus Kills Triple Negative Breast Cancer Cells and Tumor Cells")
Penn State College of Medicine researchers claim that a virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice.
"Women with breast cancer do not routinely receive testing for the androgen receptor," Richer commented.
The investigators hypothesized that maximal estrogen receptor activity depends on the androgen receptor's nuclear localization. This process, Richer said, involves the receptor moving itself and the hormone molecule, to which it is bound, inside the nucleus of a cell, where the receptor "does its important business."
Richer and her co-workers then tested a new anti-androgen drug called enzalutamide, which is approved for treatment of prostate cancer. Unlike older anti-androgen drugs, which allow the androgen receptor to go to the cell's nucleus, enzalutamide inhibits the ability of androgen receptors to enter the nucleus, Richer said.
"If the androgen receptor is outside the nucleus, both estrogen and androgen driven tumor growth is inhibited," she explained.
In preclinical models (human cells and mice) of estrogen receptor-positive breast cancers that also were positive for the androgen receptor, enzalutamide treatment inhibited both androgen- and estrogen-controlled tumor growth, Richer reported. Further, the combination of enzalutamide and tamoxifen decreased estrogen-driven tumor growth better than either drug alone.
Another study by Richer's team, to be presented Monday (OR38-2), found that breast cancers that are estrogen receptor negative ("triple negative") can also rely on the androgen receptor for growth. In preclinical models of estrogen receptor-negative tumors, enzalutamide treatment decreased tumor growth by 85 percent, according to the abstract.
"Our research suggests that the androgen receptor may serve as a therapeutic target in both estrogen receptor-positive and negative breast cancers," Richer said.
Source: Eurekalert
New Virus Kills Triple Negative Breast Cancer Cells and Tumor Cells
Penn State College of Medicine researchers claim that a virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice.
Advertisement
"Women with breast cancer do not routinely receive testing for the androgen receptor," Richer commented.
The investigators hypothesized that maximal estrogen receptor activity depends on the androgen receptor's nuclear localization. This process, Richer said, involves the receptor moving itself and the hormone molecule, to which it is bound, inside the nucleus of a cell, where the receptor "does its important business."
Richer and her co-workers then tested a new anti-androgen drug called enzalutamide, which is approved for treatment of prostate cancer. Unlike older anti-androgen drugs, which allow the androgen receptor to go to the cell's nucleus, enzalutamide inhibits the ability of androgen receptors to enter the nucleus, Richer said.
"If the androgen receptor is outside the nucleus, both estrogen and androgen driven tumor growth is inhibited," she explained.
In preclinical models (human cells and mice) of estrogen receptor-positive breast cancers that also were positive for the androgen receptor, enzalutamide treatment inhibited both androgen- and estrogen-controlled tumor growth, Richer reported. Further, the combination of enzalutamide and tamoxifen decreased estrogen-driven tumor growth better than either drug alone.
Another study by Richer's team, to be presented Monday (OR38-2), found that breast cancers that are estrogen receptor negative ("triple negative") can also rely on the androgen receptor for growth. In preclinical models of estrogen receptor-negative tumors, enzalutamide treatment decreased tumor growth by 85 percent, according to the abstract.
"Our research suggests that the androgen receptor may serve as a therapeutic target in both estrogen receptor-positive and negative breast cancers," Richer said.
Source: Eurekalert
Racial Differences in Sentinel Lymph Node Biopsy in Women With Breast Cancer
The rates of increase in black women using sentinel lymph node biopsy (SLNB) to stage early breast cancer is slower than white women, during 2002 to 2007.
Advertisement
 Women With a Specific Gene Mutation Face Higher Risk of Dying from a Type of Breast CancerNew study reveals women with a specific gene mutation have a higher risk of dying from a type of breast cancer. The study raises the prospects of targeted drugs. | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
New study findings delineate how aging affects the immune response following Spinal cord injury (SCI) and highlight the participation of the spinal cord meninges in repair.
A recent clinical trial suggests that the first medication therapy to reduce the progression of nearsightedness in children could be on the way.
Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.
Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.
Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.